Guangdong Provincial Drug Exchange has announced the results of the national joint review and pricing for medical products in March 2025. This initiative aims to enhance transparency, ensure fair pricing, and support the efficient distribution of medical products.
Key Policy Highlights
- Information Disclosure
- Purpose: To provide the public and medical institutions with accurate pricing information for newly listed medical products.
- Details: The announcement includes detailed pricing information for medical products that passed the review without objections during the display period.
- Pricing Mechanism
- Negotiation: Products are included in the negotiated pricing procurement range, allowing medical institutions to purchase at prices not exceeding the listed prices.
- Efficiency: Streamlined processes ensure timely inclusion of products in the procurement range.
- Post-Review Handling
- Information Verification: Products with pending information verification or incomplete registration certificates will be listed after verification is completed.
- Transparency: Ensuring all listed products meet regulatory standards and pricing requirements.
Policy Orientation and Industry Implications
The national joint review and pricing policy reflects Guangdong’s strategic focus on:
- Transparency: Enhancing transparency in medical product pricing through public disclosure.
- Fair Pricing: Ensuring medical institutions can access products at fair and reasonable prices.
- Efficiency: Promoting efficient distribution and procurement processes to support healthcare delivery.
Conclusion
Guangdong’s approach to national medical product review and pricing sets a benchmark for regional medical product management, emphasizing transparency, fair pricing, and efficient distribution. Medical product enterprises should align with these guidelines to ensure smooth operations and contribute to healthcare efficiency.-China Health Reform Pulse
Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1907745298520739840